SureTrader SPDR Advertisement SPDR Advertisement
Home > Boards > US Listed > Biotechs >

BioTime, Inc. (BTX)

Add BTX Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator
Search This Board:
Last Post: 3/3/2015 1:28:25 PM - Followers: 61 - Board type: Free - Posts Today: 1


BioTime, Inc.  (BTX)





Company Information:

BioTime, Inc.
1301 Harbor Bay Parkway
Alameda, CA 94502

Phone: 510-521-3390
      Fax: 510-521-3389






BioTime, Inc. (NYSE AMEX: BTX) is a biotechnology company engaged in two areas of biomedical research and product development:

  • Stem cell technology and products for use in regenerative medicine.  These products and technologies are being developed and marketed by our wholly owned subsidiary Embryome Sciences, Inc.
  • Blood plasma volume expanders and related technology for use in surgery, emergency trauma treatment and other applications.  Our lead product is Hextend® which is being marketed by Hospira, Inc. and CJ CheilJedang Corp. under exclusive licenses from us


The Potential of Regenerative Medicine

Regenerative medicine refers to therapies based on human embryonic stem ("hES") cell technology that are designed to rebuild cell and tissue function lost due to degenerative disease or injury. The great scientific and public interest in regenerative medicine lies in the potential of hES cells to transform into any cell type of the human body. hES cells therefore show considerable potential as a source of new therapies for a host of currently-incurable diseases such as: diabetes, stroke, Alzheimer's and Parkinson's disease, heart failure, arthritis, muscular dystrophy, spinal cord injury, macular degeneration, hearing loss, kidney and liver failure, as well as many other disorders that may be treated by replacing diseased or damaged organ tissues. In response to the unusual potential of the field, the State of California has allocated $3 billion over the next 10 years to fund basic research, and President Obama has lifted previous restrictions for federal funding of stem cell research.

Led by Dr. Michael West, considered by many to be a founding father of the stem cell industry, BioTime has assembled an array of products and associated intellectual property that give it the potential to be a leader in this exciting new field of medicine.

We are implementing a near-term revenues strategy in the regenerative medicine field by seeking to develop and market advanced hES products and technology that can be used by researchers at universities and biopharmaceutical companies. These research-only products generally can be marketed without regulatory (FDA) approval, and are therefore relatively near-term business opportunities when compared to human therapeutic products. We may also initiate development programs for human therapeutic applications if sufficient capital becomes available to us or through joint efforts with industry partners.

BioTime is leveraging its product development strategy on two key technology platforms:

  • • An advanced iPS technology allowing the transformation of human cells of the body back to a primordial stem cell state equivalent to embryonic stem cells. Using this technology with patient specific stem cells, rather than stem cells derived from embryos donated by unrelated people, may reduce the incidence of rejection of tissue grafts.
  • ACTCellerate™ technology that permits the generation of scalable and highly purified cells of the human body.

See this link for more information:









Dr. Michael West, CEO

Dr. West is the Chief Executive Officer of BioTime, Inc. (NYSE AMEX: BTIM) and Embryome Sciences, Inc. of Alameda, California. The Companies are focused on developing an array of research and therapeutic products using human embryonic stem cell technology. He received his Ph.D. from Baylor College of Medicine in 1989 concentrating on the biology of cellular aging. He has focused his academic and business career on the application of developmental biology to the age-related degenerative disease. He was the Founder of Geron Corporation of Menlo Park, California (Nasdaq: GERN) and from 1990 to 1998 he was a Director, and Vice President, where he initiated and managed programs in telomerase diagnostics, oligonucleotide-based telomerase inhibition as anti-tumor therapy, and the cloning and use of telomerase in telomerase-mediated therapy wherein telomerase is utilized to immortalize human cells. From 1995 to 1998 he organized and managed the research collaboration between Geron and its academic collaborators James Thomson and John Gearhart that led to the first isolation of human embryonic stem and human embryonic germ cells. From 1998 to 2007 he was President and Chief Scientific Officer at Advanced Cell Technology, Inc. (OTCBB: ACTC) where he managed programs in animal cloning, human somatic cell nuclear transfer, retinal differentiation, and ACTCellerate, a technology for the multiplex derivation and characterization of clonal human embryonic progenitor cell lines. 

Dr. West's complete CV and background on his research interests are available online at:





Recent News:








Transfer Agent:

American Stock Transfer & Trust Company
59 Maiden Lane
New York 10038


Investor Relations:

Judith Segall

VP of Administration, Corporate Secretary

Phone:  510.521.3390 ext 301






All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.

Also, keep in mind that moderators may or may not have a position in said stock.   Being a moderator isn't a sign of endorsement.


Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement:


  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
BTX News: BioTime Announces First Patient Treated in Pivotal Clinical Trial of Renevia™ for HIV-Associated Lipoatrophy 02/24/2015 09:12:00 AM
BTX News: Current Report Filing (8-k) 02/24/2015 09:11:00 AM
BTX News: Current Report Filing (8-k) 02/24/2015 06:06:38 AM
BTX News: Cell Cure Neurosciences Ltd. Provides Update on its Product Development and Partnering Activities 02/17/2015 08:45:00 AM
BTX News: Current Report Filing (8-k) 02/17/2015 08:31:13 AM
#485   BIOTIME IS A VERY INTERESTING GROUP OF COMPANIES! envirogym 03/03/15 01:28:25 PM
#484   Yes, with the pick up of the GERN tradetrak 03/02/15 10:05:54 PM
#483   This company is one of the leaders in envirogym 03/02/15 01:43:06 PM
#482   A disruption to the cosmetic surgery industry if One Flap 03/02/15 11:30:27 AM
#481   Thanks. I hadn't seen the 2/25 release. tradetrak 02/28/15 09:55:18 PM
#480   ON THEIR WEB SITE, CURRENT NEWS RELEASE. envirogym 02/28/15 01:35:38 PM
#479   Do you have some actual news or is tradetrak 02/27/15 08:55:00 PM
#477   NEW PATENTS COMING OUT OF THIS COMPANY EVERY DAY. envirogym 02/19/15 03:16:29 PM
#476   Biotime Warrants h2145h 02/19/15 11:10:20 AM
#475   New info and new patent... tradetrak 02/17/15 01:13:10 PM
#474   While BTX has many, many irons in the Adi2 02/12/15 03:52:07 PM
#473   Given the timeline and the many BTX components tradetrak 02/10/15 09:05:03 PM
#472   I'm new to BTX. Please give views h2145h 02/09/15 11:35:00 AM
#471   Agreed! tradetrak 01/26/15 08:55:35 PM
#470   BTX $$$$ Will be the leader if not Stock Guy777 01/26/15 06:56:19 PM
#468 Stock Guy777 01/26/15 06:43:42 PM
#467   I WONDER IF THEY CAN GIVE A SYNOPSIS, envirogym 01/26/15 06:40:38 PM
#466   Nice SA article by JMY Investments... tradetrak 01/26/15 01:30:06 PM
#465   Up we go again. Five dollar break around Stock Guy777 01/26/15 12:31:53 PM
#464   With the news of all these patents today Stock Guy777 01/26/15 10:57:00 AM
#463   I'm not seeing anything since the "New Insider" tradetrak 01/23/15 01:54:08 PM
#462   Any privy to Regulatory filling, confidential treatment order? poonch1ne 01/22/15 11:48:30 AM
#461   WTH is up with today's trading? Profit taking? tradetrak 01/20/15 04:14:53 PM
#460   WELL I'M BACK OVER MY ENTRY POINT SO envirogym 01/12/15 04:40:16 PM
#459   I love "under the radar"! diannedawn 01/12/15 10:16:06 AM
#458   Same here. I love C###, but over time Adi2 01/10/15 02:04:47 PM
#457   We are finally waking up! People realizing the Stock Guy777 01/08/15 12:56:30 PM
#456   Interesting! ht Stock Guy777 01/08/15 12:54:48 PM
#455   Yes Karin, just as we saw our risk poonch1ne 01/06/15 02:19:45 AM
#454   The only way to reduce risk playing biotech KarinCA 01/05/15 11:33:18 PM
#453   Yeah and on great volume! Liking it big time. tradetrak 01/05/15 09:31:09 PM
#452   4.15 today, 52 week high. poonch1ne 01/05/15 06:33:32 PM
#451   Another write up from Agora today, this time poonch1ne 01/05/15 06:27:51 PM
#450   Yeah, I was in it a few years tradetrak 01/02/15 10:47:31 PM
#449   I'd love it if something happened to this One Flap 01/02/15 05:53:50 PM
#448   If today's action thus far is any indication tradetrak 01/02/15 12:33:36 PM
#447   $BTX DD Notes ~ stocktrademan 12/28/14 01:29:45 PM
#446   The details of this company appear to be Stock_Strategies 12/26/14 11:23:09 AM
#445   Oops. Sorry, saw the Dec 20 post date tradetrak 12/25/14 11:00:32 PM
#444   Nice find. Thanks. Here's another, but longer: tradetrak 12/25/14 01:47:55 PM
#443   must watch. Adi2 12/25/14 07:42:29 AM
#442   know that some repost these, but will not poonch1ne 12/24/14 08:13:03 AM
#441   Were long way away from recognition yet. This Adi2 12/24/14 04:32:13 AM
#440   You wouldn't happen to have a link to tradetrak 12/23/14 10:49:35 PM
#439   Great write up from Agora financial yesterday. Many poonch1ne 12/23/14 03:59:20 PM
#438   Hmmmm. Interesting action on volume. End of year tradetrak 12/22/14 09:37:10 PM
#437   Nice recap Adi2. Given today's action, maybe the tradetrak 12/22/14 02:40:07 PM
#436   We have now: 2 P2, 1 P1, 3 pivotal trials Adi2 12/20/14 02:03:14 AM